logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Sinan Liu

Tianjin Chengjian University
H指数:25
被引数:2,376

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Metallic glass roadmap

金属玻璃路线图

Materials Futures
IF10.8
2025-09-260
OAAI
Wei-Hua Wang; Rui Zhao; Rong Han; Ying-Hui Shang; Yong Yang; Song-Ling Liu; Shi-Yun Zhang; Yuan-Chao Hu; Yi-Tao Sun; Ming-Xing Li; Ling-Xiang Shi; Ke-Fu Yao; Jiang Ma; Hai-Bo Ke; Yong Zhao; Bo Zhang; Xing Tong; Hai-Yang Bai; Si-Nan Liu; Zhen-Duo Wu; Si Lan; Qi Cheng; Jihan Zhou; Heng Kang; Peng-Fei Guan; Zhen-Wei Wu; Hua-Ping Zhang; Peng Luo; Lai-Quan Shen; Hai-Bin Yu; Sen-Kuan Meng; Zheng Wang; Hai-Long Peng; Shuai Ren; Yu Tong; Li-Jian Song; Jun-Tao Huo; Jun-Qiang Wang; Jing-Li Ren; Peng Wang; Mao-Zhi Li; Bei-Bei Fan; Bo Huang; Jun Yi; Xi-Lei Bian; Qing Wang; Gang Wang; Min-Qiang Jiang; Yin-Xiao Wang; Zheng-Wang Zhu; Hai-Feng Zhang; Chuan-Kun Zhou; Ming Liu; Shao-Fan Zhao; Jing Zhou; Xue-Song Li; Bao-An Sun; Zhen Lu; Shu-Jie Pang; Hu-Yang Li; Huai-Jun Lin; Ji Wang; Xing-Yao Wang; Yu-Han Shen; Cheng-Rong Cao; Ben-Zhen Tang; Peng Yu
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications (May, 10.1016/j.annonc.2023.05.009, 2023)
ANNALS OF ONCOLOGY
IF65.4
2024-05-010
OA
Burotto, M.; Zvirbule, Z.; Mochalova, A.; Runglodvatana, Y.; Herraez-Baranda, L.; Liu, S. N.; Chan, P.; Shearer-Kang, E.; Liu, X.; Tosti, N.; Zanghi, J. A.; Leutgeb, B.; Felip, E.
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
ANNALS OF ONCOLOGY
IF65.4
2023-08-0113
OA
Burotto, M.; Zvirbule, Z.; Mochalova, A.; Runglodvatana, Y.; Herraez-Baranda, L.; Liu, S. N.; Chan, P.; Shearer-Kang, E.; Liu, X.; Tosti, N.; Zanghi, J. A.; Leutgeb, B.; Felip, E.

研究方向

暂未获取到该数据
S
Si Lan
H 指数:37论文数:238被引数:6,660
X
Xun‐Li Wang
H 指数:58论文数:385被引数:1.1万
J
Jiacheng Ge
H 指数:13论文数:47被引数:552
S
Shu Fu
H 指数:13论文数:37被引数:408
Yang REN 封面图
Yang REN
H 指数:132论文数:1,661被引数:7.0万
Z
Zhenduo Wu
H 指数:22论文数:79被引数:2,107
T
Tao Feng
H 指数:48论文数:440被引数:8,700
H
Horst Hahn
H 指数:90论文数:1,078被引数:3.5万
M
Mengyang Yan
H 指数:11论文数:27被引数:363
H
Huiqiang Ying
H 指数:9论文数:25被引数:218